Showing 2871-2880 of 5973 results for "".
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- Suzanne Olbricht, MD, Named New Chief of Dermatology at Beth Israel Deaconess Medical Centerhttps://practicaldermatology.com/news/suzanne-olbricht-md-named-new-chief-of-dermatology-at-beth-israel-deaconess-medical-center/2458278/Suzanne Olbricht, MD, is the new Chief of Dermatology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She will also serve as President of the American Academy of Dermatology in 2018. From 1983 to 1997, Dr. Olbricht worked as a staff derma
- No Biopsy Required? Non-Invasive Skin Cancer Test May Offer Quick Diagnosishttps://practicaldermatology.com/news/no-biopsy-required-non-invasive-skin-cancer-test-may-offer-quick-diagnosis/2458284/A new non-invasive imaging technique may accurately detect skin cancer without surgical biopsy. Multiphoton microscopy of mitochondria accurately identified melanomas and basal cell carcinomas by detecting abnormal clusters of mitochondria in both types of skin cancer, according to resear
- New From Skinceuticals: H.A. Intensifierhttps://practicaldermatology.com/news/new-from-skinceuticals-ha-intensifier/2458285/SkinCeuticals is rolling out their new H.A. Intensifier, a corrective hyaluronic acid serum. Key ingredients include 10% Proxylane, a proprietary ingredient, to support hyaluronic acid levels and
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- ZO Skin Health Introduces Oraser Cellulite Control Creamhttps://practicaldermatology.com/news/zo-skin-health-introduces-oraser-cellulite-control-cream/2458295/ZO Skin Health's new Oraser Cellulite Control is formulated to offer instant firming effects, visibly improve the skin's texture, and reduce the appearance of cellulite. In addition to smoothing skin and diminishing the "orange peel" appearance, the crème also helps impro
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only
- Medical Spa State of the Industry Statistical Study Now Openhttps://practicaldermatology.com/news/medical-spa-state-of-the-industry-statistical-study-now-open/2458301/During the past five years, the medical spa industry has grown and evolved to a point where it has become one of the most exciting and lucrative new industries in the country. Because of this, it is now more important than ever that the industry have its own credible state of the industry report.
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Topline Results from Novan's SB204 Phase 3 Pivotal Trials: Inconsistent Across Trialshttps://practicaldermatology.com/news/novan-reports-topline-results-from-sb204-phase-3-pivotal-trials/2458306/Novan, Inc. (NASDAQ: